Abstract
Sulforaphane (SFN), one of naturally occurring isothiocyanates (ITCs), has huge cancer chemopreventive potential. It modulates cell death, cell cycle, angiogenesis, susceptibility to carcinogens, invasion and metastasis and possesses antioxidant activities. It functions as an inhibitor of phase I enzymes and also as an inducer of phase II detoxification enzymes through different ways. NF-E2- related factor-2(Nrf-2), as well as mitogen-activated protein kinase (MAPK), is regulated by SFN. Intriguingly, strong evidence has showed the dark side of Nrf-2: stable upregulation of Nrf-2-mediated survival pathway would protect cancer cells from a subset of chemotherapeutic agents tested. This suggested that overexpression of Nrf-2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents. Hence, future studies will focus on clarifying the exact time and dose of SFN to modulate the Nrf-2 signal pathway during chemotherapy and the efficacy of coadministration of Nrf-2 modulators during chemotherapy in order to make full use of the beneficial effect of this agent while eliminating the potential side effects.
Keywords: Anti-Cancer, Chemopreventive agent, Chemoresistance, Combination therapy, Isothiocyanates, Signaling pathway, Sulforaphane, Systemic toxicity, Glueosinolates, pancreatic
Anti-Cancer Agents in Medicinal Chemistry
Title:Dual Roles of Sulforaphane in Cancer Treatment
Volume: 12 Issue: 9
Author(s): Tongzhen Xu, Dongmei Ren, Xuefei Sun and Guotao Yang
Affiliation:
Keywords: Anti-Cancer, Chemopreventive agent, Chemoresistance, Combination therapy, Isothiocyanates, Signaling pathway, Sulforaphane, Systemic toxicity, Glueosinolates, pancreatic
Abstract: Sulforaphane (SFN), one of naturally occurring isothiocyanates (ITCs), has huge cancer chemopreventive potential. It modulates cell death, cell cycle, angiogenesis, susceptibility to carcinogens, invasion and metastasis and possesses antioxidant activities. It functions as an inhibitor of phase I enzymes and also as an inducer of phase II detoxification enzymes through different ways. NF-E2- related factor-2(Nrf-2), as well as mitogen-activated protein kinase (MAPK), is regulated by SFN. Intriguingly, strong evidence has showed the dark side of Nrf-2: stable upregulation of Nrf-2-mediated survival pathway would protect cancer cells from a subset of chemotherapeutic agents tested. This suggested that overexpression of Nrf-2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents. Hence, future studies will focus on clarifying the exact time and dose of SFN to modulate the Nrf-2 signal pathway during chemotherapy and the efficacy of coadministration of Nrf-2 modulators during chemotherapy in order to make full use of the beneficial effect of this agent while eliminating the potential side effects.
Export Options
About this article
Cite this article as:
Xu Tongzhen, Ren Dongmei, Sun Xuefei and Yang Guotao, Dual Roles of Sulforaphane in Cancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (9) . https://dx.doi.org/10.2174/187152012803529691
DOI https://dx.doi.org/10.2174/187152012803529691 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry Recent US Patents on Extracellular Matrix in Tissue Engineering and Regenerative Medicine
Recent Patents on Regenerative Medicine Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Spectral Perspective on the Electromagnetic Activity of Cells
Current Topics in Medicinal Chemistry Analysis of Key GO Terms and KEGG Pathways Associated with Carcinogenic Chemicals
Combinatorial Chemistry & High Throughput Screening Headache in Multiple Sclerosis - Pharmacological Aspects
Current Pharmaceutical Design Telocytes as a Source of Progenitor Cells in Regeneration and Repair Through Granulation Tissue
Current Stem Cell Research & Therapy Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Azelaic Acid: A Promising Agent for Dermatological Applications
Current Drug Therapy Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells
Current Drug Discovery Technologies Predictive Biomarkers and Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma
Current Medicinal Chemistry New Features in the Treatment of Androgen-Independent Prostate Cancer
Current Pharmaceutical Design Antioxidant Therapeutic Approaches Toward Amelioration of the Pulmonary Pathophysiological Damaging Effects of Ionizing Irradiation
Current Respiratory Medicine Reviews Mesenchymal Stem Cells for Treatment of CNS Injury
Current Neuropharmacology A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Spinal Microvascular Expression of PV-1 is Associated with Inflammation, Perivascular Astrocyte Loss, and Diminished EC Glucose Transport Potential in Acute SCI
Current Neurovascular Research